GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shionogi & Co Ltd (TSE:4507) » Definitions » Cash And Cash Equivalents

Shionogi (TSE:4507) Cash And Cash Equivalents : 円358,090 Mil (As of Mar. 2024)


View and export this data going back to 1949. Start your Free Trial

What is Shionogi Cash And Cash Equivalents?

Shionogi's quarterly cash and cash equivalents increased from Sep. 2023 (円252,371.00 Mil) to Dec. 2023 (円284,787.00 Mil) and increased from Dec. 2023 (円284,787.00 Mil) to Mar. 2024 (円358,090.00 Mil).

Shionogi's annual cash and cash equivalents increased from Mar. 2022 (円254,420.00 Mil) to Mar. 2023 (円309,224.00 Mil) and increased from Mar. 2023 (円309,224.00 Mil) to Mar. 2024 (円358,090.00 Mil).


Shionogi Cash And Cash Equivalents Historical Data

The historical data trend for Shionogi's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shionogi Cash And Cash Equivalents Chart

Shionogi Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 208,861.00 276,173.00 254,420.00 309,224.00 358,090.00

Shionogi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 309,224.00 289,076.00 252,371.00 284,787.00 358,090.00

Shionogi Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Shionogi  (TSE:4507) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Shionogi Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Shionogi's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Shionogi (TSE:4507) Business Description

Traded in Other Exchanges
Address
1-8, Doshomachi 3-chome, Chuo-ku, Osaka, JPN, 541-0045
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late stage drug discovery through commercial production. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Shionogi (TSE:4507) Headlines

No Headlines